Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5036
Abstract: 5036Background: Predictive biomarkers are needed to improve the proportion of pts with mCRPC that may benefit from anti-PD-1/PD-L1 ICB. A comprehensive characterization of both genomic alterations ... read more here.
Keywords: checkpoint blockade; immune checkpoint; blockade icb; anti immune ... See more keywords
Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9510
Abstract: 9510Background: Nivolumab (nivo) and combination ipilimumab (ipi) + nivo are highly active in pts with unresectable and stage IV MM. Nivo is also safe and effective adjuvant treatment for MM pts wi... read more here.
Keywords: checkpoint blockade; immune checkpoint; blockade icb; icb patients ... See more keywords